Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
James Flory MD, MSCE

James Flory MD, MSCE

Assistant Professor, Department of Health Policy and Research, Weill Cornell Medical College; Assistant Attending, Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York

James Flory MD, MSCE is an Assistant Professor in the Department of Health Policy and Research at Weill Cornell Medical College, and an Assistant Attending on the Endocrinology Service at Memorial Sloan Kettering Cancer Center. He is supported by funding from the Agency for Healthcare Research and Quality, K08 HS023898, to study metformin tolerability and persistence.

Disclosures

No disclosures to report.

Recent Contributions to PracticeUpdate:

  1. Metformin–Cimetidine Interaction and the Risk of Lactic Acidosis in Renal Failure
  2. Metformin Monotherapy in US Veterans With T2DM and Stage 3 CKD
  3. Safety of Metformin in Patients With Diabetes and CKD
  4. Hospitalization for Lactic Acidosis in Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
  5. Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus
  6. Association of Treatment With Metformin vs Sulfonylurea With MACE Among Patients With Diabetes and Reduced Kidney Function
  7. Long-Term Weight Loss With Metformin or Lifestyle Intervention in Diabetes
  8. Metformin Use and Cardiovascular Events in Patients With Type 2 Diabetes and Chronic Kidney Disease
  9. Use of Metformin in CKD, CHF, and CLD Associated With Reduced Mortality

Most Read This Week

Recently Updated